EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

A systematic review and meta‐analysis of the impacts of germline pharmacogenomics on severe toxicity and symptom burden in adult patients with cancer

Senthil Lingaratnam iD, Mahek Shah, Joseph Nicolazzo iD, Michael Michael iD, John F Seymour iD, Paul James iD, Smaro Lazarakis iD, Sherene Loi iD, Carl M J Kirkpatrick iD

Clinical and Translational Science · 2024

DOI: 10.1111/cts.13781 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Senthil Lingaratnam und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Neoplasms, Pharmacogenetics. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical application of Pharmacogenomics (PGx) has improved patient safety. However, comprehensive PGx testing has not been widely adopted in clinical practice, and significant opportunities exist to further optimize PGx in cancer care. This systematic review and meta‐analysis aim to evaluate the safety outcomes of reported PGx‐guided strategies (Analysis 1) and identify well‐studied emerging pharmacogenomic variants that predict severe toxicity and symptom burden (Analysis 2) in patients with cancer. We searched MEDLINE, EMBASE, CENTRAL, clinicaltrials.gov , and International Clinical Trials Registry Platform from inception to January 2023 for clinical trials or comparative studies evaluating PGx strategies or unconfirmed pharmacogenomic variants. The primary outcomes were severe adverse events (SAE; ≥ grade 3) or symptom burden with pain and vomiting as defined by trial protocols and assessed by trial investigators. We calculated pooled overall relative risk (RR) and 95% confidence interval (95%CI) using random effects models. PROSPERO, registration number CRD42023421277. Of 6811 records screened, six studies were included for Analysis 1, 55 studies for Analysis 2. Meta‐analysis 1 (five trials, 1892 participants) showed a lower absolute incidence of SAEs with PGx‐guided strategies compared to usual therapy, 16.1% versus 34.0% (RR = 0.72, 95%CI 0.57–0.91, p = 0.006, I 2 = 34%). Meta‐analyses 2 identified nine medicine(class)‐variant pairs of interest across the TYMS , ABCB1 , UGT1A1 , HLA‐DRB1 , and OPRM1 genes. Application of PGx significantly reduced rates of SAEs in patients with cancer. Emergent medicine‐variant pairs herald further research into the expansion and optimization of PGx to improve systemic anti‐cancer and supportive care medicine safety and efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsPharmacogeneticsAdultHumansAntineoplastic AgentsGerm-Line MutationPharmacogenomic TestingPharmacogenomic VariantsSymptom Burden

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Pharmacy Department, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
  • Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia.
  • Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia.
  • Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia.

ORCID-Profile: Senthil Lingaratnam, Joseph Nicolazzo, Michael Michael, John F Seymour, Paul James, Smaro Lazarakis, Sherene Loi, Carl M J Kirkpatrick

Zitieren

APA

Lingaratnam, S., Shah, M., Nicolazzo, J., Michael, M., Seymour, J. F., James, P., Lazarakis, S., Loi, S., & Kirkpatrick, C. M. J. (2024). A systematic review and meta‐analysis of the impacts of germline pharmacogenomics on severe toxicity and symptom burden in adult patients with cancer. Clinical and Translational Science. https://doi.org/10.1111/cts.13781

Vancouver

Lingaratnam S, Shah M, Nicolazzo J, Michael M, Seymour JF, James P, et al. A systematic review and meta‐analysis of the impacts of germline pharmacogenomics on severe toxicity and symptom burden in adult patients with cancer. Clinical and Translational Science. 2024. doi:10.1111/cts.13781

BibTeX
@article{Lingaratnam2024,
  author = {Lingaratnam, Senthil and Shah, Mahek and Nicolazzo, Joseph and Michael, Michael and Seymour, John F and James, Paul and Lazarakis, Smaro and Loi, Sherene and Kirkpatrick, Carl M J},
  title = {A systematic review and meta‐analysis of the impacts of germline pharmacogenomics on severe toxicity and symptom burden in adult patients with cancer},
  journal = {Clinical and Translational Science},
  year = {2024},
  doi = {10.1111/cts.13781}
}
Kostenlos starten →